Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REPLIGEN CORP Director's Dealing 2024

Mar 19, 2024

30826_dirs_2024-03-19_616284bc-c11f-4291-ade5-fb2a15755934.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2024-03-18

Reporting Person: Pax Margaret (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-03-18 Common Stock A 92 $0.00 Acquired 92 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-03-18 Stock Option (Right to Buy) $194.25 A 195 Acquired 2034-03-18 Common Stock (195) Direct
2024-03-18 Stock Option (Right to Buy) $194.25 A 2236 Acquired 2034-03-18 Common Stock (2236) Direct

Footnotes

F1: Ms. Pax was awarded 92 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 16, 2024, the date of the annual meeting of the Company's shareholders. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: Award vests in full on May 16, 2024, the date of the annual meeting of the Company's shareholders.

F3: The shares vest in equal annual instalments over a three-year period with each such vesting date occurring on the earlier of the anniversary of the grant date or the date of the annual meeting of the Company's shareholders of the applicable year of such three-year period.